Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMV pp65-LAMP mRNA-pulsed autologous dendritic cells
- Development stage
- Phase 2
- Lead developer
- Immunomic Therapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
CMV pp65-LAMP mRNA-pulsed autologous dendritic cells is an investigational therapeutic cancer vaccine designed for the treatment of glioblastoma multiforme (GBM). The therapy consists of patient-derived (autologous) dendritic cells that are pulsed with messenger RNA encoding the human cytomegalovirus (CMV) matrix protein pp65 and lysosome-associated membrane protein (LAMP). This engineering directs the antigen to lysosomes within the dendritic cells, enhancing presentation via MHC-II molecules and stimulating a robust cytotoxic T-cell response against tumor cells expressing CMV pp65. The approach aims to induce a targeted immune attack on glioblastoma while sparing healthy tissue. The therapy is being developed by Immunomic Therapeutics and Celldex Therapeutics and has reached Phase 2 clinical trials in patients with newly diagnosed GBM[1][3][4][5][7].
- Other names
- autologous CMV-pp65-flLAMP mRNA-loaded dendritic cell vaccineautologous CMV-pp65-shLAMP-1 mRNA loaded dendritic cell vaccine
02
Targets
pp65 (Cytomegalovirus phosphoprotein 65)
Beyond the preview
Go deeper on CMV pp65-LAMP mRNA-pulsed autologous dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMV pp65-LAMP mRNA-pulsed autologous dendritic cells.